



PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete If Known

Substitute for form 1449/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

1

| | |
|----------------------|-------------------------|
| Application Number | 10/697,135 (Conf #9753) |
| Filing Date | 30 October 2003 |
| First Named Inventor | Peter G. KLIMKO, et al. |
| Art Unit | 1614 |
| Examiner Name | |

Attorney Docket Number

2439 US

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------|-----------------------|---|----------------|
| Z.F | A1 | Butler et. al., "Suberoylanilide Hydroxamic Acid, an Inhibitor of Histone Deacetylase, Suppresses the Growth of Prostate Cancer Cells in Vitro and in Vivo," CANCER RESEARCH, 60:5165-5170 (2000) | |
| Z.F | A2 | Mori H et al., "Cyclic tetrapeptide compounds as histone deacetylase inhibitors and their use in therapy". Database CA on STN, Chemical Abstracts, No. 132:288798, WO 2002074298 (Sep 2002) | |
| Z.F | A3 | Naka M et al., "Preparation of n-acylaminoalkane-hydroxamic acids as IL-6 production inhibitors", abstract, Database CA on STN, Chemical Abstracts, No. 137:247516 | |
| Z.F | A4 | Timmermann S et al., "Histone acetylation and disease", CELLULAR AND MOLECULAR LIFE SCIENCES, 58:728-736 (2001) | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

| | | | |
|--------------------|-----------------|-----------------|---------|
| Examiner Signature | <i>Zahn Foy</i> | Date Considered | 4/25/07 |
|--------------------|-----------------|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.